Abstract Number: 219 • 2015 ACR/ARHP Annual Meeting
Targeted Deep Resequencing Identifies MRP4/ABCC4 as a Gout Risk Locus in the New Zealand Mä�ori and Pacific Island Populations
Background/Purpose: Genetic variants in uric acid transporters that control serum urate levels in Europeans have been identified by genome-wide association studies. However there is no…Abstract Number: 220 • 2015 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Reveals Association of the Transferrin Receptor Locus with Gout
Background/Purpose: Acute gouty arthritis results from an innate immune response to monosodium urate (MSU) crystals deposited in the joints and soft tissues of hyperuricaemic individuals.…Abstract Number: 221 • 2015 ACR/ARHP Annual Meeting
Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study
Background/Purpose: Hyperuricaemia and secondary gout are well-recognised complications of diuretic use. Variants in ABCG2 and SLC2A9 have been identified as the two major genetic risk…Abstract Number: 222 • 2015 ACR/ARHP Annual Meeting
Serum Delta Neutrophil Index Measurement for Differentiating Acute Gouty Arthritis and Cellulitis in Normouricemic Patients
Background/Purpose: Diagnosis of a patient who comes with acute foot pain is often challenging, because both acute gouty arthritis and cellulitis share common clinical manifestations…Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…Abstract Number: 224 • 2015 ACR/ARHP Annual Meeting
Silent Monosodium Urate Crystals Deposits in Asymptomatic Hyperuricemia Lead to a Higher Need for Coronary Revascularization
Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. In a preliminary, cross-sectional study we found that silent deposits of monosodium urate (MSU)…Abstract Number: 225 • 2015 ACR/ARHP Annual Meeting
Gout Patients Present Carotid Plaques at Presentation in Spite of Low-Risk Cardiovascular Score
Gout patients present carotid plaques at presentation in spite of low-risk cardiovascular score.Background/Purpose: Gout is associated with an increased cardiovascular (CV) risk related to high…Abstract Number: 226 • 2015 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both
Background/Purpose: Osteoarthritis (OA) and gout are each associated with increased cardiovascular disease (CVD), but their relative impacts on CV risk are not known. We compared…Abstract Number: 227 • 2015 ACR/ARHP Annual Meeting
Impact of Gout on the Risk of Atrial Fibrillation
Background/Purpose: To examine the risk of atrial fibrillation (AF) at the time of first diagnosis of gout compared to matched controls and to follow incident…Abstract Number: 228 • 2015 ACR/ARHP Annual Meeting
Gout and Risk of Non-Vertebral Osteoporotic Fracture
Background/Purpose: Prior studies suggest an association between osteoporosis, systemic inflammation and pro-inflammatory cytokines such as IL-1 and IL-6. Gout is a common inflammatory arthritis characterized…Abstract Number: 229 • 2015 ACR/ARHP Annual Meeting
Uric Acid and Incident Dementia over 10 Years
Background/Purpose: In patients with gout, maintaining the serum uric acid (SUA) levels too low with ULT is a matter of concern because UA is thought…Abstract Number: 230 • 2015 ACR/ARHP Annual Meeting
Serum Uric Acid As Short Term Mortality Predictor in the Acute Care Setting
Background/Purpose: Many studies have showed that the serum uric acid (SUA) is an independent predictor of adverse cardiovascular events and all-cause mortality, but some studies…Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting
Uric Acid Levels Predict Mortality in Women
Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…Abstract Number: 232 • 2015 ACR/ARHP Annual Meeting
Hyperuricemia, Urate Lowering Therapy and Kidney Function: A Systemic Review and Meta-Analysis
Background/Purpose: To determine whether hyperuricemia is associated with deterioration of kidney function and to examine whether urate-lowering therapies (ULTs) can improve or maintain kidney function.…Abstract Number: 233 • 2015 ACR/ARHP Annual Meeting
Gout Does Not Decrease the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis
Gout Does Not Decrease the Risk of Parkinson's Disease: A Systematic Review and Meta-analysisBackground/Purpose: Uric acid is a potent anti-oxidant and hyperuricemia is well-linked to…